Alzheimer’s disease attacks the cells of the brain and neurotransmitters, affecting the way brain functions, memory and behaviour. There is no known cure for the disease, and current approaches focus on helping people maintain mental function, manage behavioural symptoms, and slow down specific problems, such as memory loss. Two categories of drugs are approved for Alzheimer’s disease treatment: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.
Some of the key facts of Alzheimer’s disease report
1. Alzheimer’s Disease affects an estimated 6.08 million people in the United States.
2. Approximately 200,000 people younger than 65 years constitute the younger-onset population of Alzheimer’s Disease in the US.
3. The females show a higher proportion of Alzheimer’s Disease Prevalence as compared to males in the 7MM.
Scope of Alzheimer’s disease report
- The Alzheimer’s disease (AD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Alzheimer’s disease (AD) Epidemiology Report and Model provide an overview of the risk factors and global trends of Alzheimer’s disease (AD) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight about the historical and forecasted patient pool of Alzheimer’s disease (AD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Alzheimer’s disease (AD)
- The report provides the segmentation of the Alzheimer’s disease (AD) epidemiology
Table of contents
1. Key Insights
2. Executive Summary of Alzheimer’s disease (AD)
3. Alzheimer’s disease (AD): Disease Background and Overview
3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis
4. Patient Journey
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in the 7MM (2017- 2030)
5.4. United States Epidemiology
5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United States (2017- 2030)
5.5. EU-5 Country-wise Epidemiology
5.5.1. Germany Epidemiology
5.5.1.1. Alzheimer’s disease (AD) Epidemiology Scenario in Germany (2017- 2030)
5.5.2. France Epidemiology
5.5.2.1. Alzheimer’s disease (AD) Epidemiology Scenario in France (2017- 2030)
5.5.3. Italy Epidemiology
5.5.3.1. Alzheimer’s disease (AD) Epidemiology Scenario in Italy (2017- 2030)
5.5.4. Spain Epidemiology
5.5.4.1. Alzheimer’s disease (AD) Epidemiology Scenario in Spain (2017- 2030)
5.5.5. United Kingdom Epidemiology
5.5.5.1. Alzheimer’s disease (AD) Epidemiology Scenario in the United Kingdom (2017-2030)
5.6. Japan Epidemiology
5.6.1. Alzheimer’s disease (AD) Epidemiology Scenario in Japan (2017- 2030)
6. Treatment Algorithm, Current Treatment, and Medical Practices
6.1. Alzheimer’s disease (AD) Treatment and Management
6.2. Alzheimer’s disease (AD) Treatment Algorithm
7. KOL Views
8. Unmet Needs
9. Appendix
9.1. Bibliography
9.2. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/